ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1398

Myokine Myostatin Is a Novel Predictor of One-year Radiographic Progression in Patients with Rheumatoid Arthritis
Abstract Number: 1048

Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study
Abstract Number: 1877

Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies
Abstract Number: 2263

Nanotherapeutic Approaches for the Treatment of Post-traumatic Osteoarthritis
Abstract Number: 0528

Nasal Epithelial Gene Expression Profiling Preceding Relapse in Patients with Granulomatosis with Polyangiitis
Abstract Number: 0143

National Multicenter Study of 80 Patients with Refractory Uveitis Due to Immune-Mediated Inflammatory Diseases Treated with Certolizumab Pegol
Abstract Number: 0571

National Rollout of a Medication Safety Dashboard to Improve Testing for Latent Infections Among Biologic/targeted Synthetic DMARD Users Within the Veterans Health Administration: Initial Results
Abstract Number: 1662

Nationwide Distribution of Other Connective Tissue Disease (OCTD) and Systemic Sclerosis (SSc) in Areas of Environmental Concern
Abstract Number: 2025

Natural History of Sjögren’s Disease from the National Institutes of Health Cohort
Abstract Number: 1189

Natural Language Processing of Chest CT Reports as a Novel Method of Identifying RA-ILD in Real-World Data
Abstract Number: 0053

Natural Microbial Exposure Increases Susceptibility of C57BL/6 Mice to Collagen-induced Arthritis
Abstract Number: 1103

Needs Assessment of Musculoskeletal Ultrasound Training in North American Pediatric Rheumatology Fellowship Programs
Abstract Number: 0620

Neovascularization Is Altered by Rheumatoid Arthritis Synovial Fibroblasts and Canstatin in Vitro and in Vivo
Abstract Number: 0242

Neural Networks for Distinguishing Rheumatoid Arthritis from Psoriatic Arthritis by Using Magnetic Resonance Imaging
Abstract Number: 1918

Neurobiological Mechanisms of a Remote-Delivered Mind-body Intervention for Knee Osteoarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].